Ratings Bigtincan Holdings Limited

Equities

BTH

AU000000BTH6

Market Closed - Australian S.E. Other stock markets 11:40:53 16/05/2024 am IST			5-day change	1st Jan Change
0.155 ^AUD	+3.33%		0.00%	-22.50%

11/04	Bigtincan Holdings Logs AU$30 Million Revenue in Fiscal Q3; Shares Surge 19%	MT
18/03	Bigtincan Holdings Limited(ASX:BTH) dropped from S&P/ASX All Ordinaries Index	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The company is in a robust financial situation considering its net cash and margin position.
The stock, which is currently worth 2024 to 0.64 times its sales, is clearly overvalued in comparison with peers.
The company's share price in relation to its net book value makes it look relatively cheap.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last few months, analysts have been revising downwards their earnings forecast.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIGTINCAN HOLDINGS LIMITED	-22.50%	6.18Cr	-
MODERNA, INC.	+32.34%	4.95TCr	B-
IQVIA HOLDINGS INC.	+2.28%	4.26TCr	B
LONZA GROUP AG	+49.11%	4.25TCr	A
CELLTRION, INC.	-5.26%	2.91TCr	C
ICON PUBLIC LIMITED COMPANY	+12.42%	2.66TCr	B-
ALNYLAM PHARMACEUTICALS, INC.	-23.48%	1.86TCr	B
BIO-TECHNE CORPORATION	+8.47%	1.32TCr	B+
MEDPACE HOLDINGS, INC.	+30.52%	1.25TCr	C+
UNITED THERAPEUTICS CORPORATION	+24.00%	1.21TCr	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes